{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:27:55Z","timestamp":1782818875165,"version":"3.54.5"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T00:00:00Z","timestamp":1276646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T00:00:00Z","timestamp":1276646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1038\/npp.2010.75","type":"journal-article","created":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T14:15:39Z","timestamp":1276697739000},"page":"2060-2071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Cannabinoid CB1 Receptor Immunoreactivity in the Prefrontal Cortex: Comparison of Schizophrenia and Major Depressive Disorder"],"prefix":"10.1038","volume":"35","author":[{"given":"Stephen M","family":"Eggan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel R","family":"Stoyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D","family":"Verrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,16]]},"reference":[{"key":"BFnpp201075_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.brainresrev.2006.04.001","volume":"52","author":"S Akbarian","year":"2006","unstructured":"Akbarian S, Huang HS (2006). Molecular and cellular mechanisms of altered GAD1\/GAD67 expression in schizophrenia and related disorders. Brain Res Rev 52: 293\u2013304.","journal-title":"Brain Res Rev"},{"key":"BFnpp201075_CR2","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1176\/ajp.156.10.1580","volume":"156","author":"M Akil","year":"1999","unstructured":"Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR et al (1999). Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156: 1580\u20131589.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201075_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0301-0082(98)00087-2","volume":"58","author":"A Ameri","year":"1999","unstructured":"Ameri A (1999). The effects of cannabinoids on the brain. Prog Neurobiol 58: 315\u2013348.","journal-title":"Prog Neurobiol"},{"key":"BFnpp201075_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1054\/plef.2001.0352","volume":"66","author":"BS Basavarajappa","year":"2002","unstructured":"Basavarajappa BS, Hungund BL (2002). Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview. Prostaglandins Leukot Essent Fatty Acids 66: 287\u2013299.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"BFnpp201075_CR5","first-page":"202","volume-title":"Neurobiology of Mental Illness","author":"M Beneyto","year":"2009","unstructured":"Beneyto M, Sibille E, Lewis DA (2009). Human postmortem brain research in mental illness syndromes. In: Charney DS, Nestler EJ (eds). Neurobiology of Mental Illness. Oxford University Press: New York. pp 202\u2013214."},{"key":"BFnpp201075_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00406-002-0366-5","volume":"252","author":"G Bersani","year":"2002","unstructured":"Bersani G, Orlandi V, Kotzalidis GD, Pancheri P (2002). Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci 252: 86\u201392.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BFnpp201075_CR7","doi-asserted-by":"publisher","first-page":"6845","DOI":"10.1523\/JNEUROSCI.0442-05.2005","volume":"25","author":"AL Bodor","year":"2005","unstructured":"Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, Hajos N et al (2005). Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci 25: 6845\u20136856.","journal-title":"J Neurosci"},{"key":"BFnpp201075_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.biopsych.2006.12.001","volume":"62","author":"M Bortolato","year":"2007","unstructured":"Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A et al (2007). Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62: 1103\u20131110.","journal-title":"Biol Psychiatry"},{"key":"BFnpp201075_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1124\/mol.60.1.155","volume":"60","author":"CS Breivogel","year":"2001","unstructured":"Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60: 155\u2013163.","journal-title":"Mol Pharmacol"},{"key":"BFnpp201075_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/schbul\/sbn135","volume":"35","author":"PF Buckley","year":"2009","unstructured":"Buckley PF, Miller BJ, Lehrer DS, Castle DJ (2009). Psychiatric comorbidities and schizophrenia. Schizophr Bull 35: 383\u2013402.","journal-title":"Schizophr Bull"},{"key":"BFnpp201075_CR11","doi-asserted-by":"publisher","first-page":"9800","DOI":"10.1073\/pnas.0703472104","volume":"104","author":"HD Burns","year":"2007","unstructured":"Burns HD, Van Laere K, Sanabria-Bohorquez S, Hamill TG, Bormans G, Eng WS et al (2007). [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A 104: 9800\u20139805.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFnpp201075_CR12","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","volume":"370","author":"R Christensen","year":"2007","unstructured":"Christensen R, Kristensen PK, Bartels EM, Blidda H, Astrup A (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370: 1706\u20131713.","journal-title":"Lancet"},{"key":"BFnpp201075_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev.neuro.26.041002.131128","volume":"27","author":"BW Connors","year":"2004","unstructured":"Connors BW, Long MA (2004). Electrical synapses in the mammalian brain. Annu Rev Neurosci 27: 393\u2013418.","journal-title":"Annu Rev Neurosci"},{"key":"BFnpp201075_CR14","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/npp.2009.36","volume":"34","author":"DA Cruz","year":"2009","unstructured":"Cruz DA, Weaver CL, Lovallo EM, Melchitzky DS, Lewis DA (2009). Selective alterations in postsynaptic markers of chandelier cell inputs to cortical pyramidal neurons in subjects with schizophrenia. Neuropsychopharmacology 34: 2112\u20132124.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp201075_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","volume":"57","author":"DC D'Souza","year":"2005","unstructured":"D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G et al (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57: 594\u2013608.","journal-title":"Biol Psychiatry"},{"key":"BFnpp201075_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0165-1781(95)02720-3","volume":"59","author":"SR Daviss","year":"1995","unstructured":"Daviss SR, Lewis DA (1995). Local circuit neurons of the prefrontal cortex in schizophrenia: selective increase in the density of calbindin-immunoreactive neurons. Psychiatry Res 59: 81\u201396.","journal-title":"Psychiatry Res"},{"key":"BFnpp201075_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1476-511X-2-5","volume":"2","author":"N De Marchi","year":"2003","unstructured":"De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003). Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2: 5.","journal-title":"Lipids Health Dis"},{"key":"BFnpp201075_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0306-4522(00)00552-2","volume":"103","author":"B Dean","year":"2001","unstructured":"Dean B, Sundram S, Bradbury R, Scarr E, Copolov D (2001). Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103: 9\u201315.","journal-title":"Neuroscience"},{"key":"BFnpp201075_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12264-007-0051-9","volume":"23","author":"C Deng","year":"2007","unstructured":"Deng C, Han M, Huang XF (2007). No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neurosci Bull 23: 341\u2013347.","journal-title":"Neurosci Bull"},{"key":"BFnpp201075_CR20","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/sj.npp.1300710","volume":"30","author":"K-A Dorph-Petersen","year":"2005","unstructured":"Dorph-Petersen K-A, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA (2005). The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 30: 1649\u20131661.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp201075_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/(SICI)1096-9861(20000626)422:2<159::AID-CNE1>3.0.CO;2-1","volume":"422","author":"M Egertov\u00e1","year":"2000","unstructured":"Egertov\u00e1 M, Elphick MR (2000). Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 422: 159\u2013171.","journal-title":"J Comp Neurol"},{"key":"BFnpp201075_CR22","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/archpsyc.65.7.772","volume":"65","author":"SM Eggan","year":"2008","unstructured":"Eggan SM, Hashimoto T, Lewis DA (2008). Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 65: 772\u2013784.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp201075_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/cercor\/bhj136","volume":"17","author":"SM Eggan","year":"2007","unstructured":"Eggan SM, Lewis DA (2007). Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex 17: 175\u2013191.","journal-title":"Cereb Cortex"},{"key":"BFnpp201075_CR24","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/cercor\/bhp179","volume":"20","author":"SM Eggan","year":"2010","unstructured":"Eggan SM, Mizoguchi Y, Stoyak SR, Lewis DA (2010). Development of cannabinoid 1 receptor protein and messenger RNA in monkey dorsolateral prefrontal cortex. Cereb Cortex 20: 1164\u20131174.","journal-title":"Cereb Cortex"},{"key":"BFnpp201075_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevNeurobiol.v14.i1.10","volume":"14","author":"B Elvevag","year":"2000","unstructured":"Elvevag B, Goldberg TE (2000). Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14: 1\u201321.","journal-title":"Crit Rev Neurobiol"},{"key":"BFnpp201075_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1517\/13543784.15.2.107","volume":"15","author":"K Fagerstrom","year":"2006","unstructured":"Fagerstrom K, Balfour DJ (2006). Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin Investig Drugs 15: 107\u2013116.","journal-title":"Expert Opin Investig Drugs"},{"key":"BFnpp201075_CR27","doi-asserted-by":"publisher","first-page":"9770","DOI":"10.1523\/JNEUROSCI.3027-04.2004","volume":"24","author":"M Galarreta","year":"2004","unstructured":"Galarreta M, Erdelyi F, Szabo G, Hestrin S (2004). Electrical coupling among irregular-spiking GABAergic interneurons expressing cannabinoid receptors. J Neurosci 24: 9770\u20139778.","journal-title":"J Neurosci"},{"key":"BFnpp201075_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0376-8716(98)00189-6","volume":"55","author":"L Garcia-Gil","year":"1999","unstructured":"Garcia-Gil L, Romero J, Ramos JA, Fernandez-Ruiz JJ (1999). Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to delta9-tetrahydrocannabinol. Drug Alcohol Depend 55: 127\u2013136.","journal-title":"Drug Alcohol Depend"},{"key":"BFnpp201075_CR29","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","volume":"29","author":"A Giuffrida","year":"2004","unstructured":"Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J et al (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29: 2108\u20132114.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp201075_CR30","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/archpsyc.57.11.1061","volume":"57","author":"A Guidotti","year":"2000","unstructured":"Guidotti A, Auta J, Davis JM, Gerevini VD, Dwivedi Y, Grayson DR et al (2000). Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder. Arch Gen Psychiatry 57: 1061\u20131069.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp201075_CR31","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1046\/j.1460-9568.2000.00217.x","volume":"12","author":"N Hajos","year":"2000","unstructured":"Hajos N, Katona I, Naiem SS, Mackie K, Ledent C, Mody I et al (2000). Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12: 3239\u20133249.","journal-title":"Eur J Neurosci"},{"key":"BFnpp201075_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0306-4522(01)00287-1","volume":"106","author":"N Hajos","year":"2001","unstructured":"Hajos N, Ledent C, Freund TF (2001). Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106: 1\u20134.","journal-title":"Neuroscience"},{"key":"BFnpp201075_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/sj.mp.4002011","volume":"13","author":"T Hashimoto","year":"2008","unstructured":"Hashimoto T, Arion D, Unger T, Maldonado-Aviles JG, Morris HM, Volk DW et al (2008a). Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 13: 147\u2013161.","journal-title":"Mol Psychiatry"},{"key":"BFnpp201075_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1176\/appi.ajp.2007.07081223","volume":"165","author":"T Hashimoto","year":"2008","unstructured":"Hashimoto T, Bazmi HH, Mirnics K, Wu Q, Sampson AR, Lewis DA (2008b). Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry 165: 479\u2013489.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201075_CR35","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1523\/JNEUROSCI.4159-06.2007","volume":"27","author":"Y Hashimotodani","year":"2007","unstructured":"Hashimotodani Y, Ohno-Shosaku T, Kano M (2007). Presynaptic monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus. J Neurosci 27: 1211\u20131219.","journal-title":"J Neurosci"},{"key":"BFnpp201075_CR36","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/sj.bjp.0707347","volume":"152","author":"JG Horswill","year":"2007","unstructured":"Horswill JG, Bali U, Shaaban S, Keily JF, Jeevaratnam P, Babbs AJ et al (2007). PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 152: 805\u2013814.","journal-title":"Br J Pharmacol"},{"key":"BFnpp201075_CR37","first-page":"1689","volume":"47","author":"AG Horti","year":"2006","unstructured":"Horti AG, Fan H, Kuwabara H, Hilton J, Ravert HT, Holt DP et al (2006). 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med 47: 1689\u20131696.","journal-title":"J Nucl Med"},{"key":"BFnpp201075_CR38","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1093\/cercor\/bhg084","volume":"13","author":"MW Howard","year":"2003","unstructured":"Howard MW, Rizzuto DS, Caplan JB, Madsen JR, Lisman J, Aschenbrenner-Scheibe R et al (2003). Gamma oscillations correlate with working memory load in humans. Cereb Cortex 13: 1369\u20131374.","journal-title":"Cereb Cortex"},{"key":"BFnpp201075_CR39","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/29.4.6166661","volume":"29","author":"S-M Hsu","year":"1981","unstructured":"Hsu S-M, Raine L, Fanger H (1981). Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577\u2013580.","journal-title":"J Histochem Cytochem"},{"key":"BFnpp201075_CR40","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1196\/annals.1316.064","volume":"1025","author":"BL Hungund","year":"2004","unstructured":"Hungund BL, Basavarajappa BS (2004). Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors. Ann N Y Acad Sci 1025: 515\u2013527.","journal-title":"Ann N Y Acad Sci"},{"key":"BFnpp201075_CR41","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/sj.mp.4001376","volume":"9","author":"BL Hungund","year":"2004","unstructured":"Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB et al (2004). Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 9: 184\u2013190.","journal-title":"Mol Psychiatry"},{"key":"BFnpp201075_CR42","doi-asserted-by":"publisher","first-page":"9506","DOI":"10.1523\/JNEUROSCI.21-23-09506.2001","volume":"21","author":"I Katona","year":"2001","unstructured":"Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N et al (2001). Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 21: 9506\u20139518.","journal-title":"J Neurosci"},{"key":"BFnpp201075_CR43","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0306-4522(00)00286-4","volume":"100","author":"I Katona","year":"2000","unstructured":"Katona I, Sperlagh B, Magloczky Z, Santha E, Kofalvi A, Czirjak S et al (2000). GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 100: 797\u2013804.","journal-title":"Neuroscience"},{"key":"BFnpp201075_CR44","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1523\/JNEUROSCI.19-11-04544.1999","volume":"19","author":"I Katona","year":"1999","unstructured":"Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K et al (1999). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19: 4544\u20134558.","journal-title":"J Neurosci"},{"key":"BFnpp201075_CR45","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1523\/JNEUROSCI.0309-06.2006","volume":"26","author":"I Katona","year":"2006","unstructured":"Katona I, Urban GM, Wallace M, Ledent C, Jung KM, Piomelli D et al (2006). Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 26: 5628\u20135637.","journal-title":"J Neurosci"},{"key":"BFnpp201075_CR46","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1523\/JNEUROSCI.4872-05.2006","volume":"26","author":"Y Kawamura","year":"2006","unstructured":"Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, Watanabe M et al (2006). The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 26: 2991\u20133001.","journal-title":"J Neurosci"},{"key":"BFnpp201075_CR47","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nn1262","volume":"7","author":"J Kim","year":"2004","unstructured":"Kim J, Alger BE (2004). Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci 7: 697\u2013698.","journal-title":"Nat Neurosci"},{"key":"BFnpp201075_CR48","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00702-007-0660-5","volume":"114","author":"D Koethe","year":"2007","unstructured":"Koethe D, Llenos IC, Dulay JR, Hoyer C, Torrey EF, Leweke FM et al (2007). Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 114: 1055\u20131063.","journal-title":"J Neural Transm"},{"key":"BFnpp201075_CR49","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/00001756-199906030-00008","volume":"10","author":"FM Leweke","year":"1999","unstructured":"Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999). Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10: 1665\u20131669.","journal-title":"Neuroreport"},{"key":"BFnpp201075_CR50","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nrn1648","volume":"6","author":"DA Lewis","year":"2005","unstructured":"Lewis DA, Hashimoto T, Volk DW (2005). Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6: 312\u2013324.","journal-title":"Nat Rev Neurosci"},{"key":"BFnpp201075_CR51","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1172\/JCI37335","volume":"119","author":"DA Lewis","year":"2009","unstructured":"Lewis DA, Sweet RA (2009). Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J Clin Invest 119: 706\u2013716.","journal-title":"J Clin Invest"},{"key":"BFnpp201075_CR52","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1001\/archpsyc.1994.03950040017002","volume":"51","author":"DH Linszen","year":"1994","unstructured":"Linszen DH, Dingemans PM, Lenior ME (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51: 273\u2013279.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp201075_CR53","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/nn1521","volume":"8","author":"JK Makara","year":"2005","unstructured":"Makara JK, Mor M, Fegley D, Szabo SI, Kathuria S, Astarita G et al (2005). Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8: 1139\u20131141.","journal-title":"Nat Neurosci"},{"key":"BFnpp201075_CR54","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.phrs.2007.09.003","volume":"56","author":"RA Mangieri","year":"2007","unstructured":"Mangieri RA, Piomelli D (2007). Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacol Res 56: 360\u2013366.","journal-title":"Pharmacol Res"},{"key":"BFnpp201075_CR55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejphar.2006.11.013","volume":"557","author":"EM Marco","year":"2007","unstructured":"Marco EM, Granstrem O, Moreno E, Llorente R, Adriani W, Laviola G et al (2007). Subchronic nicotine exposure in adolescence induces long-term effects on hippocampal and striatal cannabinoid-CB1 and mu-opioid receptors in rats. Eur J Pharmacol 557: 37\u201343.","journal-title":"Eur J Pharmacol"},{"key":"BFnpp201075_CR56","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1046\/j.1460-9568.1999.00847.x","volume":"11","author":"G Marsicano","year":"1999","unstructured":"Marsicano G, Lutz B (1999). Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11: 4213\u20134225.","journal-title":"Eur J Neurosci"},{"key":"BFnpp201075_CR57","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1046\/j.1460-9568.2003.02852.x","volume":"18","author":"YM Morozov","year":"2003","unstructured":"Morozov YM, Freund TF (2003). Post-natal development of type 1 cannabinoid receptor immunoreactivity in the rat hippocampus. Eur J Neurosci 18: 1213\u20131222.","journal-title":"Eur J Neurosci"},{"key":"BFnpp201075_CR58","first-page":"231","volume":"35","author":"HM Morris","year":"2009","unstructured":"Morris HM, Lewis DA (2009). GABA-related mRNA expression in the dorsolateral prefrontal cortex (DLPFC) of subjects with bipolar or major depressive disorder. Schizophr Bull 35: 231\u2013232.","journal-title":"Schizophr Bull"},{"key":"BFnpp201075_CR59","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nrn2253","volume":"8","author":"RM Murray","year":"2007","unstructured":"Murray RM, Morrison PD, Henquet C, Di Forti M (2007). Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 8: 885\u2013895.","journal-title":"Nat Rev Neurosci"},{"key":"BFnpp201075_CR60","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s00221-006-0503-x","volume":"172","author":"KA Newell","year":"2006","unstructured":"Newell KA, Deng C, Huang XF (2006). Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 172: 556\u2013560.","journal-title":"Exp Brain Res"},{"key":"BFnpp201075_CR61","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/cne.903360307","volume":"336","author":"KM Oeth","year":"1993","unstructured":"Oeth KM, Lewis DA (1993). Postnatal development of the cholecystokinin innervation of monkey prefrontal cortex. J Comp Neurol 336: 400\u2013418.","journal-title":"J Comp Neurol"},{"key":"BFnpp201075_CR62","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1523\/JNEUROSCI.22-10-03864.2002","volume":"22","author":"T Ohno-Shosaku","year":"2002","unstructured":"Ohno-Shosaku T, Tsubokawa H, Mizushima I, Yoneda N, Zimmer A, Kano M (2002). Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci 22: 3864\u20133872.","journal-title":"J Neurosci"},{"key":"BFnpp201075_CR63","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1176\/ajp.156.11.1709","volume":"156","author":"JN Pierri","year":"1999","unstructured":"Pierri JN, Chaudry AS, Woo T-U, Lewis DA (1999). Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry 156: 1709\u20131719.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201075_CR64","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0006-8993(02)03055-X","volume":"948","author":"M Pistis","year":"2002","unstructured":"Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa GL et al (2002). Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 948: 155\u2013158.","journal-title":"Brain Res"},{"key":"BFnpp201075_CR65","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1124\/mol.105.016162","volume":"68","author":"MR Price","year":"2005","unstructured":"Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R et al (2005). Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68: 1484\u20131495.","journal-title":"Mol Pharmacol"},{"key":"BFnpp201075_CR66","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/cercor\/5.4.307","volume":"5","author":"G Rajkowska","year":"1995","unstructured":"Rajkowska G, Goldman-Rakic PS (1995). Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria. Cereb Cortex 5: 307\u2013322.","journal-title":"Cereb Cortex"},{"key":"BFnpp201075_CR67","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1523\/JNEUROSCI.20-01-00485.2000","volume":"20","author":"SG Rao","year":"2000","unstructured":"Rao SG, Williams GV, Goldman-Rakic PS (2000). Destruction and creation of spatial tuning by disinhibition: GABAA blockade of prefrontal cortical neurons engaged by working memory. J Neurosci 20: 485\u2013494.","journal-title":"J Neurosci"},{"key":"BFnpp201075_CR68","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1176\/appi.ajp.2009.09040574","volume":"167","author":"A Reichenberg","year":"2010","unstructured":"Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RS, Murray RM et al (2010). Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry 167: 160\u2013169.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201075_CR69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1096\/fj.01-0593com","volume":"16","author":"R Rimondini","year":"2002","unstructured":"Rimondini R, Arlinde C, Sommer W, Heilig M (2002). Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol. FASEB J 16: 27\u201335.","journal-title":"FASEB J"},{"key":"BFnpp201075_CR70","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/(SICI)1098-2396(199811)30:3<298::AID-SYN7>3.0.CO;2-6","volume":"30","author":"J Romero","year":"1998","unstructured":"Romero J, Berrendero F, Manzanares J, Perez A, Corchero J, Fuentes JA et al (1998). Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 30: 298\u2013308.","journal-title":"Synapse"},{"key":"BFnpp201075_CR71","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/0091-3057(95)00023-P","volume":"51","author":"J Romero","year":"1995","unstructured":"Romero J, Garcia L, Fernandez-Ruiz JJ, Cebeira M, Ramos JA (1995). Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol. Pharmacol Biochem Behav 51: 731\u2013737.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFnpp201075_CR72","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S0169-328X(96)00277-X","volume":"46","author":"J Romero","year":"1997","unstructured":"Romero J, Garcia-Palomero E, Castro JG, Garcia-Gil L, Ramos JA, Fernandez-Ruiz JJ (1997). Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res 46: 100\u2013108.","journal-title":"Brain Res Mol Brain Res"},{"key":"BFnpp201075_CR73","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1097\/00001756-199412000-00022","volume":"5","author":"T Rubino","year":"1994","unstructured":"Rubino T, Massi P, Patrini G, Venier I, Giagnoni G, Parolaro D (1994). Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study. Neuroreport 5: 2493\u20132496.","journal-title":"Neuroreport"},{"key":"BFnpp201075_CR74","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0166-4328(88)90023-X","volume":"31","author":"T Sawaguchi","year":"1988","unstructured":"Sawaguchi T, Matsumura M, Kubota K (1988). Delayed response deficit in monkeys by locally disturbed prefrontal neuronal activity by bicuculline. Behav Brain Res 31: 193\u2013198.","journal-title":"Behav Brain Res"},{"key":"BFnpp201075_CR75","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1615\/CritRevNeurobiol.v15.i2.10","volume":"15","author":"LJ Sim-Selley","year":"2003","unstructured":"Sim-Selley LJ (2003). Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15: 91\u2013119.","journal-title":"Crit Rev Neurobiol"},{"key":"BFnpp201075_CR76","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00210-005-1074-2","volume":"371","author":"S Sundram","year":"2005","unstructured":"Sundram S, Copolov D, Dean B (2005). Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol 371: 428\u2013433.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFnpp201075_CR77","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/npp.2008.67","volume":"34","author":"RA Sweet","year":"2009","unstructured":"Sweet RA, Henteleff RA, Zhang W, Sampson AR, Lewis DA (2009). Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. Neuropsychopharmacology 34: 374\u2013389.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp201075_CR78","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2967\/jnumed.109.067074","volume":"51","author":"GE Terry","year":"2010","unstructured":"Terry GE, Hirvonen J, Liow JS, Zoghbi SS, Gladding R, Tauscher JT et al (2010). Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands. J Nucl Med 51: 112\u2013120.","journal-title":"J Nucl Med"},{"key":"BFnpp201075_CR79","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1113\/jphysiol.2003.058198","volume":"556","author":"J Trettel","year":"2004","unstructured":"Trettel J, Fortin DA, Levine ES (2004). Endocannabinoid signalling selectively targets perisomatic inhibitory inputs to pyramidal neurones in juvenile mouse neocortex. J Physiol 556: 95\u2013107.","journal-title":"J Physiol"},{"key":"BFnpp201075_CR80","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00213-009-1608-2","volume":"206","author":"L Uriguen","year":"2009","unstructured":"Uriguen L, Garcia-Fuster MJ, Callado LF, Morentin B, La Harpe R, Casado V et al (2009). Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl) 206: 313\u2013324.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFnpp201075_CR81","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.biopsych.2004.11.033","volume":"57","author":"KY Vinod","year":"2005","unstructured":"Vinod KY, Arango V, Xie S, Kassir SA, Mann JJ, Cooper TB et al (2005). Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry 57: 480\u2013486.","journal-title":"Biol Psychiatry"},{"key":"BFnpp201075_CR82","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/archpsyc.1992.01820050018002","volume":"49","author":"J Volavka","year":"1992","unstructured":"Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E et al (1992). Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 49: 354\u2013361.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp201075_CR83","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/cercor\/12.10.1063","volume":"12","author":"DW Volk","year":"2002","unstructured":"Volk DW, Pierri JN, Fritschy J-M, Auh S, Sampson AR, Lewis DA (2002). Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex 12: 1063\u20131070.","journal-title":"Cereb Cortex"},{"key":"BFnpp201075_CR84","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0006-3223(01)01252-5","volume":"50","author":"DR Weinberger","year":"2001","unstructured":"Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK et al (2001). Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50: 825\u2013844.","journal-title":"Biol Psychiatry"},{"key":"BFnpp201075_CR85","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0006-8993(91)90897-5","volume":"544","author":"TM Westlake","year":"1991","unstructured":"Westlake TM, Howlett AC, Ali SF, Paule MG, Scallet AC, Slikker Jr W (1991). Chronic exposure to delta 9-tetrahydrocannabinol fails to irreversibly alter brain cannabinoid receptors. Brain Res 544: 145\u2013149.","journal-title":"Brain Res"},{"key":"BFnpp201075_CR86","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.neuropharm.2008.07.026","volume":"55","author":"JL Wiley","year":"2008","unstructured":"Wiley JL, Kendler SH, Burston JJ, Howard DR, Selley DE, Sim-Selley LJ (2008). Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats. Neuropharmacology 55: 1183\u20131190.","journal-title":"Neuropharmacology"},{"key":"BFnpp201075_CR87","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.npp.1301402","volume":"33","author":"F Yasuno","year":"2008","unstructured":"Yasuno F, Brown AK, Zoghbi SS, Krushinski JH, Chernet E, Tauscher J et al (2008). The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain. Neuropsychopharmacology 33: 259\u2013269.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp201075_CR88","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pnpbp.2003.11.005","volume":"28","author":"K Zavitsanou","year":"2004","unstructured":"Zavitsanou K, Garrick T, Huang XF (2004). Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28: 355\u2013360.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFnpp201075_CR89","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0169-328X(98)00232-0","volume":"62","author":"S Zhuang","year":"1998","unstructured":"Zhuang S, Kittler J, Grigorenko EV, Kirby MT, Sim LJ, Hampson RE et al (1998). Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Brain Res Mol Brain Res 62: 141\u2013149.","journal-title":"Brain Res Mol Brain Res"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/npp201075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/npp201075","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/npp201075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T16:19:19Z","timestamp":1685636359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp201075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,16]]},"references-count":89,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["BFnpp201075"],"URL":"https:\/\/doi.org\/10.1038\/npp.2010.75","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,16]]},"assertion":[{"value":"22 January 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"David A Lewis currently receives investigator-initiated research support from the BMS Foundation, Bristol-Myers Squibb, Curridium, and Pfizer, and in 2007\u20132009 served as a consultant in the areas of target identification and validation and new compound development to AstraZeneca, BioLine RX, Bristol-Myers Squibb, Hoffman-Roche, Lilly, Merck, Neurogen, and SK Life Science. All other authors declare that, except for income received from their primary employer, no financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional service, and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}